View ValuationChengDa Pharmaceuticals 将来の成長Future 基準チェック /06現在、 ChengDa Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長18.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20High number of new directorsIndependent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025.お知らせ • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang Chinaお知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025お知らせ • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang Chinaお知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 37% over the past year.お知らせ • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China.Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China.お知らせ • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.お知らせ • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.お知らせ • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).Board Change • Mar 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ping Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ChengDa Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XSEC:301201 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026458-4-1346N/A12/31/2025406-12-3534N/A9/30/2025374-52-17537N/A6/30/2025352-40-2255N/A3/31/2025309-48-298-32N/A12/31/2024333-28-25829N/A9/30/202439870-189104N/A6/30/202441287-132150N/A3/31/202441390-74162N/A12/31/202341491-33192N/A9/30/202336676-20181N/A6/30/202336171-98100N/A3/31/2023405100-98107N/A1/1/2023411106-15848N/A9/30/2022432122-1369N/A6/30/2022438115-11644N/A3/31/2022436106-8379N/A1/1/2022416100-5683N/A9/30/2021396126N/AN/AN/A12/31/202037312165129N/A12/31/201929454N/A68N/A12/31/20182037N/A55N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 301201の予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 301201の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 301201の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 301201の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 301201の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 301201の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 12:38終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ChengDa Pharmaceuticals Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20High number of new directorsIndependent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025.
お知らせ • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
お知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.
お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
お知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.
お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.
Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).
Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 37% over the past year.
お知らせ • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China.
Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China.
お知らせ • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).
お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China.
お知らせ • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.
お知らせ • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.
Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).
Board Change • Mar 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Ping Wang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.